
Know Streck. Know Quality.
The 20-Day QC Study Isn’t a CLIA Requirement
Get your free copy! Fill out the form to download and receive our 10-page guide on molecular quality control verification.
The free Laboratory Quality Control Verification Strategic Guidance shows how control type, IQCP status and verification scope choices made early can affect how switching controls hold up through daily workflow and accreditation review.

NSPECTION-READINESS RECOMMENDATIONS
- Where CLIA and CLSI draw the line
- Where the 20-day tradition comes from
- The 1+4 Model for QC verification
- The conditions for a single confirmatory run
- Inspection-readiness recommendations
- A decision framework by control type and IQCP status
50+ years
of scientific excellence in diagnostics
42 CFR 493.1256
the primary CLIA regulation behind this guide
1 + 4
one confirmatory run plus four monitoring runs in the phased model
What’s inside the handbook
Six chapters built to take your assay from first tube to full-scale deployment, with practical tools, real-world lessons and decision frameworks in every chapter.
Section 1
The Core Argument
The core argument on 42 CFR 493.1256, and why a lot transition and a new assay are different events.
Section 2
Regulatory and Standards Framework
CLIA 493.1256, CLSI EP23, IQCP, EP19, and where the 20-day study comes from.
Section 3
Verification Requirements: New Control vs New Assay Implementation
Requirements for each event side by side: control type, IQCP impact and documentation.
Section 4
The 1+4 Model
One confirmatory run on Day 1, four monitoring runs on Days 2 to 5, and the documentation package.
Section 5
The Regulatory Argument
What the regulation requires, the conditions for a single confirmatory run, and the case for doing more.
Section 6
New Assay and Platform Implementation
Verification, IQCP and documentation for a new molecular assay or platform.
Section 7
Inspection Readiness and Accreditation
How to document the phased approach and confirm your accreditor’s expectations.
Section 8
Decision Framework
The verification approach by control type, IQCP status and institutional risk tolerance.
Section 9
Key Regulatory and Standards References
CLIA, CLSI, CMS, CAP, COLA, Joint Commission and state sources behind lot verification.
Take a look inside
Tables, decision frameworks and documentation lists you can bring into your next QC plan review.

Where the 20-day tradition comes from
The CLSI C24 scope, and where it applies.

Lot transition vs. new assay
The requirements for each event, side by side.

A decision framework
The verification approach by control type and IQCP status.
What you’ll be able to do
Know where the regulation stops. Document your reasoning. Verify at the depth your risk calls for.
Right size the verification scope when switching controls vs new assay implementation.
Match verification depth to your control type, IQCP status and institutional risk tolerance.
Build transition record that documents a structured, risk-based process for inspection.
Written for molecular and infectious disease laboratory teams
Whether your lab runs qualitative panels or quantitative viral load assays, the framework starts from the same questions: what is your control type, is your IQCP active, and what does your accreditation program expect?
Get the Laboratory Quality Control Verification Strategic Guidance
10-page PDF. We’ll email you a copy.
